Indaptus Therapeutics, Inc.
INDP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001857044
No open-market purchases or sales by Indaptus Therapeutics, Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.15M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Indaptus Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 17 | 17 | 0 |
| Shares | 1.71M | 501.1K | −1.21M (−70.7%) |
| Value | $6.81M | $1.31M | −$5.51M (−80.8%) |
New holders (4)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 19,600 | $51.0K | 0.00% |
| Harel Insurance Investments & Financial Services Ltd. | 2,888 | $7.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,705 | $4.00K | 0.00% |
| Advisor Group Holdings, Inc. | 19 | $0 | 0.00% |
Sold out (4)
Institutions that held Indaptus Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| United Capital Financial Advisers, LLC | 15,000 | $60.0K |
| UBS Group AG | 3,294 | $13.0K |
| Cambridge Trust Co | 47 | $0 |
| Creative Planning | 63 | $0 |